Hormone Therapy in Ovarian Granulosa Cell Tumors

Introduction to Hormone Therapy

• The European Society for Medical Oncology (ESMO) guidelines provide Level IV, Grade B evidence for hormonal approaches in the treatment of ovarian granulosa cell tumors 1, 2

Primary Treatment: Surgery First

• Stage IA adult granulosa cell tumors have excellent prognosis after surgery alone and do not require any adjuvant therapy, including hormonal therapy, as per the American College of Obstetricians and Gynecologists 1, 2, 3
• Debulking surgery remains the most effective treatment for advanced-stage or recurrent disease and should be pursued when feasible, according to the Society of Gynecologic Oncology 1, 2

When to Consider Hormone Therapy

• Hormone therapy should be considered specifically for patients with recurrent disease who have failed or are not candidates for surgery and chemotherapy, as recommended by the National Comprehensive Cancer Network (NCCN) 1, 2
• Adult granulosa cell tumors specifically (not juvenile type) may benefit from hormone therapy, as suggested by the American Cancer Society 1, 2

Hormone Therapy Options with Evidence Level

• Aromatase inhibitors, such as letrozole, have shown responses in recurrent disease, with evidence from the ESMO guidelines 1, 2
• Tamoxifen has documented responses in the treatment of ovarian granulosa cell tumors, according to the American Society of Clinical Oncology (ASCO) 1, 2, 4
• Progestins have shown activity in the treatment of ovarian granulosa cell tumors, as reported by the Gynecologic Oncology Group 1, 2

Critical Clinical Pitfalls

• Do not use hormone therapy as primary treatment for early-stage disease - surgery alone is curative for stage IA tumors, as stated by the American College of Surgeons 1, 2, 3
• Do not substitute hormone therapy for platinum-based chemotherapy in treatment-naive advanced disease - chemotherapy remains first-line systemic therapy, according to the NCCN 1, 2

Monitoring During Hormone Therapy

• Follow inhibin B levels if initially elevated (most sensitive marker), as recommended by the European Society for Medical Oncology (ESMO) 5
• Serial imaging with pelvic ultrasound and CT abdomen/pelvis every 3-6 months, as suggested by the American College of Radiology 1, 2, 6
• Clinical examination with pelvic exam, according to the American College of Obstetricians and Gynecologists 1, 6
• Long-term surveillance is mandatory as recurrences can occur up to 20 years after treatment, as reported by the Surveillance, Epidemiology, and End Results (SEER) program 4, 5, 6